EU grants Merck Animal Health marketing authorization for Nobivac NXT HCPChFeLV cat vaccine - MRK News | RalliesEU grants Merck Animal Health marketing authorization for Nobivac NXT HCPChFeLV cat vaccine
M
MRK• EU authorization for Nobivac NXT HCPChFeLV
- The European Commission granted marketing authorization for Merck Animal Health Ventures’ NOBIVAC NXT HCPChFeLV cat vaccine.
- The product targets five feline infectious diseases, including FeLV, with one-week onset and up to three years of immunity.
- The authorization follows a positive European Medicines Agency CVMP opinion issued on April 16, 2026.
